Financial Performance Expectations - The company expects a net loss of between 80 million and 120 million RMB for 2024, compared to a profit of 267.91 million RMB in the same period last year[3]. - The projected operating revenue for 2024 is between 2.65 billion and 2.7 billion RMB, a decrease from 2.7178734 billion RMB in the previous year[3]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of 60 million to 90 million RMB, down from a profit of 197.81 million RMB last year[3]. Revenue Challenges - The decline in revenue is attributed to a slowdown in overall demand and intensified industry competition, particularly affecting the refractive and optical projects[5]. - The implementation of national policies for centralized procurement of cataract artificial lenses has pressured the revenue from cataract projects starting from May 2024[5]. Investment and Expansion - The company has accelerated its investment expansion, opening multiple new hospitals in 2022, 2023, and 2024, which are still in the market cultivation phase[6]. - New hospitals are facing challenges due to low local brand influence and the time required to become designated by medical insurance, impacting overall revenue growth[6]. Cost and Profit Margin Impact - Rising costs and expenses, including depreciation, labor costs, and other fixed expenditures, have significantly affected the company's overall profit margins[6]. Caution and Forecast Nature - The company emphasizes that the performance forecast is based on preliminary estimates and has not been audited, with final figures to be disclosed in the 2024 annual report[7]. - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the performance forecast[7].
普瑞眼科(301239) - 2024 Q4 - 年度业绩预告